SNY
Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 42.97$. Average daily volumn in 3 months 3.04M. Market cap 94.76B
Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD Lastest price : 38.02$. Total volume : 2.93M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Sanofi (SNY)
Last Price
38.02$Change
0.02Volume
2.93M
| Previous Close | 38.00 |
| Open | 38.24 |
| Day Range | 38.01-38.58 |
| Bid | 38.03 x 1.4k |
| Ask | 38.98 x 1.2k |
| Volume | 2.93M |
| Average Volume | 3.04M |
| Market Cap | 94.76B |
| Beta | 0.42 |
| 52 Week Range | 36.91-58.10 |
| Trailing P/E | 14.79 |
| Foward P/E | 8.62 |
| Dividend (Yield %) | 4.59% |
| Ex-Dividend Date | 2022-05-26 |
Financial Details
Organization
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Market Cap:
94.76BRevenue:
39.17BTotal Assets:
120.24BTotal Cash:
10.1B
News about "Sanofi"
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
Source from : Yahoo! Sports - 2 days ago
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.See details»
Sanofi, Regeneron’s Dupixent scores another indication with first-ever approval for nodular skin disorder
Source from : ENDPOINTS NEWS - 2 days ago
Sanofi chief executive Paul Hudson told investors earlier this year that the Big Pharma was going to emphasize its sales kingpin Dupixent moving forward. He wasn't joking — the megablockbuster drug ...See details»
Sanofi uses creative camouflage in physician-targeted campaign for potential cancer biomarker
Source from : ENDPOINTS NEWS - 3 days ago
As Sanofi studies a new kind of cancer drug, it’s prepping physicians for its potential biomarker expression. Sanofi’s tusamitamab ravtansine is an antibody-drug conjugate (ADC) that targets ...See details»
French Drugmaker Sanofi Expects Positive Boost From Currency Markets in Q3
Source from : U.S. News & World Report - 4 days ago
PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since ...See details»
Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration
Source from : GEN - 4 days ago
Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today. The collaboration could generate more than $1 billion for the CRISPR drug ...See details»
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
Source from : BioPharma Dive - 4 days ago
The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment.See details»
Sanofi turns to startup Scribe to CRISPR edit new NK cell therapies for cancer
Source from : MedCity News - 4 days ago
Sanofi is collaborating with Scribe Therapeutics to use the startup’s CRISPR technology to create cell therapies based on natural killers, a type of immune cell that has cancer-killing capabilities.See details»
Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease
Source from : MarketWatch - 3 days ago
By Stephen Nakrosis Sanofi and Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved Dupixent to treat patients ...See details»
Sanofi sees positive impact from currency markets on Q3 results
Source from : Seeking Alpha - 3 days ago
Sanofi (SNY) said it expects a positive impact on its Q3 results due to movements in the currency markets.The French drugmaker said its preliminary estimate of currency impact on ...See details»
PSHAN, SANOFI Sign Agreement to Undertake COVID-19 Vaccine Hesitancy Assessment in Nigeria
Source from : This Day - 2 days ago
The Private Sector Health Alliance of Nigeria (PSHAN) and SANOFI have signed an agreement to undertake a 6 months COVID-19 Vaccine Hesitancy Assessment in Nigeria (C19-VHAN). The study which would ...See details»
Sanofi: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%
Source from : Yahoo Finance - 12 days ago
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the ...See details»
Sanofi (NASDAQ:SNY) Downgraded by TheStreet to “C+”
Source from : Defense World - 13 days ago
TheStreet lowered shares of Sanofi (NASDAQ:SNY – Get Rating) from a b- rating to a c+ rating in a research note released on Thursday, TheStreetRatingsTable reports. Several other analysts also ...See details»
Sanofi (SNY) Moves to Buy: Rationale Behind the Upgrade
Source from : Nasdaq - 11 days ago
Sanofi (SNY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...See details»
Sanofi (NASDAQ:SNY) Shares Acquired by Destiny Wealth Partners LLC
Source from : Defense World - 5 days ago
Destiny Wealth Partners LLC raised its holdings in shares of Sanofi (NASDAQ:SNY – Get Rating) by 162.0% during the second quarter, according to the company in its most recent disclosure with the ...See details»